Follow
Thierry Verbinnen
Thierry Verbinnen
Principle Scientist
Verified email at its.jnj.com
Title
Cited by
Cited by
Year
In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
O Lenz, T Verbinnen, TI Lin, L Vijgen, MD Cummings, J Lindberg, ...
Antimicrobial agents and chemotherapy 54 (5), 1878-1887, 2010
2612010
In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor
TI Lin, O Lenz, G Fanning, T Verbinnen, F Delouvroy, A Scholliers, ...
Antimicrobial agents and chemotherapy 53 (4), 1377-1385, 2009
2302009
Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies
O Lenz, T Verbinnen, B Fevery, L Tambuyzer, L Vijgen, M Peeters, ...
Journal of hepatology 62 (5), 1008-1014, 2015
1662015
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
C Sarrazin, E Lathouwers, M Peeters, B Daems, A Buelens, J Witek, ...
Antiviral research 116, 10-16, 2015
1382015
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised …
KR Reddy, S Zeuzem, F Zoulim, O Weiland, A Horban, C Stanciu, ...
The Lancet infectious diseases 15 (1), 27-35, 2015
1132015
JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection
F Zoulim, O Lenz, JJ Vandenbossche, W Talloen, T Verbinnen, I Moscalu, ...
Gastroenterology 159 (2), 521-533. e9, 2020
1002020
Tracking the Evolution of Multiple In Vitro Hepatitis C Virus Replicon Variants under Protease Inhibitor Selection Pressure by 454 Deep Sequencing
T Verbinnen, H Van Marck, I Vandenbroucke, L Vijgen, M Claes, TI Lin, ...
Journal of virology 84 (21), 11124-11133, 2010
932010
Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus–infected patients following TMC435 monotherapy
O Lenz, J de Bruijne, L Vijgen, T Verbinnen, C Weegink, H Van Marck, ...
Gastroenterology 143 (5), 1176-1178. e6, 2012
492012
Retreatment of hepatitis C virus-infected patients with direct-acting antiviral failures
JM Pawlotsky
Seminars in Liver Disease 39 (03), 354-368, 2019
422019
Chronic fatigue syndrome: A biological approach
P Englebienne, K De Meirleir
CRC Press, 2002
422002
Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data
H Janssen, J Hou, T Asselah, H Chan, F Zoulim, Y Tanaka, E Janczewska, ...
Journal of Hepatology 73, S129-S130, 2020
342020
Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype AH clinical isolates and core site-directed mutants in vitro
JM Berke, Y Tan, T Verbinnen, P Dehertogh, K Vergauwen, A Vos, O Lenz, ...
Antiviral research 144, 205-215, 2017
312017
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos (t) ide analogue in patients with chronic hepatitis B infection
HLA Janssen, J Hou, T Asselah, HLY Chan, F Zoulim, Y Tanaka, ...
Gut 72 (7), 1385-1398, 2023
292023
In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants
T Verbinnen, B Fevery, L Vijgen, T Jacobs, S De Meyer, O Lenz
Antimicrobial Agents and Chemotherapy 59 (12), 7548-7557, 2015
292015
A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin …
KR Reddy, S Zeuzem, F Zoulim, O Weiland, A Horban, C Stanciu, ...
Hepatol Int 8, S397, 2014
292014
Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro
T Verbinnen, Y Tan, G Wang, P Dehertogh, K Vergauwen, JM Neefs, ...
Journal of Antimicrobial Chemotherapy 75 (9), 2526-2534, 2020
232020
Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors
P Raboisson, O Lenz, TI Lin, D Surleraux, S Chakravarty, A Scholliers, ...
Bioorganic & medicinal chemistry letters 17 (7), 1843-1849, 2007
222007
Efficacy and safety of the siRNA JNJ-3989 and/OR the Capsid Assembly Modulator (CAM) JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB): results from the …
MF Yuen, T Asselah, IM Jacobson, MR Brunetto, HL Janssen, T Takehara, ...
Hepatology 74 (6), 1390A-1391A, 2021
212021
O004: on-treatment virologic response and tolerability of simeprevir, daclatasvir and ribavirin in patients with recurrent hepatitis c virus genotype 1b infection after …
X Forns, M Berenguer, K Herzer, M Sterneck, MF Donato, P Andreone, ...
Journal of Hepatology, S191-S192, 2015
202015
Resistance analyses of HCV isolates from patients treated with simeprevir in phase 2b/3 studies: 1101
O Lenz, B Fevery, T Verbinnen, L Tambuyzer, L Vijgen, M Peeters, ...
Hepatology 58, 743A-744A, 2013
202013
The system can't perform the operation now. Try again later.
Articles 1–20